Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

Por um escritor misterioso
Last updated 02 junho 2024
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Efficacy of COVID-19 treatments among geriatric patients: a
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Tocilizumab in patients hospitalised with COVID-19 pneumonia
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Medicina, Free Full-Text
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Systematic review and meta-analysis of anakinra, sarilumab
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
JCM, Free Full-Text
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Baricitinib versus dexamethasone for adults hospitalised with
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Frontiers The effects of combination-therapy of tocilizumab and
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Frontiers The effects of combination-therapy of tocilizumab and
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Pharmaceuticals, Free Full-Text
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or  Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus  COVID19: A Real-World Study
Role of baricitinib in COVID-19 patients: A systematic review and

© 2014-2024 rahh.de. All rights reserved.